MTOR and non-small cell lung carcinoma: The mTOR pathway is upregulated in non-small-cell lung cancer (NSCLC) and metformin inhibits its signaling by directly activating 5' adenosine monophosphate-activated protein kinase (AMPK) via liver kinase B1 (LKB1) [36].